Arcutis Biotherapeutics, Inc. (ARQT) — SC 13G Filings
All SC 13G filings from Arcutis Biotherapeutics, Inc.. Browse 6 Passive Stake Filing reports with AI-powered summaries and risk analysis.
SC 13G Filings (6)
- SC 13G Filing — Feb 13, 2024
-
Rubric Capital Takes 9.9% Stake in Arcutis Biotherapeutics
— Feb 12, 2024 Risk: low
Rubric Capital Management LP, a Delaware-based investment firm, has disclosed a significant stake in Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT). As of Decembe -
Morgan Stanley Discloses Passive Stake in Arcutis Biotherapeutics
— Feb 12, 2024 Risk: low
Morgan Stanley, a major financial institution, reported its holdings in Arcutis Biotherapeutics, Inc. (ARQT) as of December 31, 2023, through an SC 13G filing. -
Jennison Associates Discloses Initial Stake in Arcutis Biotherapeutics
— Feb 8, 2024 Risk: low
Jennison Associates LLC, a New York-based investment advisor, reported an initial beneficial ownership of Arcutis Biotherapeutics, Inc. (ARQT) common stock as o -
Point72 Takes 5.0% Stake in Arcutis Biotherapeutics
— Jan 31, 2024
Point72 Asset Management, L.P., a hedge fund, has disclosed a significant stake in Arcutis Biotherapeutics, Inc., reporting beneficial ownership of 4,836,116 sh -
BlackRock Discloses Passive Stake in Arcutis Biotherapeutics
— Jan 29, 2024
BlackRock Inc., a major investment firm, reported on January 29, 2024, that as of December 31, 2023, it holds a significant stake in Arcutis Biotherapeutics, In
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX